ArticleScientific reports2021
Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Clinicopathological characteristics, incidence trends, and prognostic factors of salivary gland secretory carcinoma: a SEER database analysis (2011-2021).European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Risk-adapted neck dissection in salivary gland carcinoma: integrating occult nodal metastasis patterns with contemporary guidelines.Frontiers in oncology · 2026Review
- Rare Tumors of Oral Cavity: A Case Report and Literature Review on Secretory Carcinoma of Minor Salivary Glands.Clinical and experimental dental research · 2025Review
- Article
- Predictive Modeling of Clinical Efficacy forCancer management and research · 2025Article
- Case series of secretory carcinoma in the parotid glands.Gland surgery · 2024Article
- Clinicopathologic characterization of secretory carcinoma of salivary gland.World journal of surgical oncology · 2024Article
- Article
- Macrocystic and non-necrotic salivary duct carcinoma of the submandibular gland: A case report.Radiology case reports · 2024Article
- Article
- Salivary gland secretory carcinoma presenting as a cervical soft tissue mass: a case report.Journal of medical case reports · 2024Review
- Clinicopathological analysis of 18 cases of secretory carcinoma of the salivary glands.Journal of dental sciences · 2024Article
- Computational pathology in cancer diagnosis, prognosis, and prediction - present day and prospects.The Journal of pathology · 2023Review
- Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.Histopathology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
This retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020. In total, 13 males and 10 females (ratio, 1.3:1) aged 10 - 69 years (median, 45 years) were enrolled in this study; the average disease duration was 2.44 years (0.25-20 years). Twenty-one patients (91.3%) had SCSG in the parotid gland, and two (8.7%) in the submandibular gland. All patients had single nodules of diameters 0.8-4.8 cm (average 2.6 cm); five with lymph node metastases, and two with distant metastases. Immunohistochemically, tumors stained positive for S-100, mammaglobin, CK7, GATA3 and pan-Trk, and negative for DOG1, P63, and calponin, with Ki-67 positivity from 1 to 50%. ETV6 gene rearrangement was confirmed in 15 patients. All patients underwent oncological resection, four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one died before the last follow-up. SCSGs are typically indolent, with a low locoregional recurrence rate and excellent survival. Prognosis is correlated to clinical stage, pathological grade, and surgical procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.